Evolus, Inc.
EOLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001570562
In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Evolus, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 96 | 115 | +19 |
| Shares | 8.61M | 16.2M | +7.62M (+88.5%) |
| Value | $111.8M | $205.3M | +$93.5M (+83.6%) |
New holders (28)
Institutions that held Evolus, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (9)
Institutions that held Evolus, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Point72 Asset Management, L.P. | 79,600 | $1.03M |
| California Public Employees Retirement System | 25,600 | $333.0K |
| Bender Robert & Associates | 25,000 | $325.0K |
| Clarkston Capital Partners, LLC | 10,170 | $132.0K |
| Highland Capital Management Fund Advisors, L.P. | 10,000 | $130.0K |
| Parallax Volatility Advisers, L.P. | 3,692 | $48.0K |
| Bank of Montreal | 1,122 | $16.0K |
| Sowell Financial Services LLC | 300 | $3.00K |
| Wealthcare Advisory Partners LLC | 100 | $1.00K |